Dr. Lara Discusses Epacadostat in Renal Cell Carcinoma

Primo N. Lara, MD
Published: Wednesday, Jul 19, 2017



Primo N. Lara, MD, associate director for translational research, UC Davis Comprehensive Cancer Center, discusses epacadostat in renal cell carcinoma (RCC).

Preliminary results from the phase II ECHO-202/KEYNOTE-037 trial showed encouraging response rates and safety signals with epacadostat plus pembrolizumab (Keytruda) in patients with metastatic RCC.

Lara says the advantages of a drug like epacadostat is that it is oral, so it provides an extra level of convenience, should it become a standard of care in the future.
 
SELECTED
LANGUAGE


Primo N. Lara, MD, associate director for translational research, UC Davis Comprehensive Cancer Center, discusses epacadostat in renal cell carcinoma (RCC).

Preliminary results from the phase II ECHO-202/KEYNOTE-037 trial showed encouraging response rates and safety signals with epacadostat plus pembrolizumab (Keytruda) in patients with metastatic RCC.

Lara says the advantages of a drug like epacadostat is that it is oral, so it provides an extra level of convenience, should it become a standard of care in the future.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How to Use Liquid Biopsies Throughout the Lung Cancer Treatment Continuum OnlineJan 31, 20191.5
Community Practice Connections™: Current Status and the Future Potential of CAR T-Cell Therapy for Lymphoid Malignancies: The Experts Weigh-In on Recent Data and Clinical ExperienceJan 31, 20192.0
Publication Bottom Border
Border Publication
x